Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Lancet Oncology Pubmed

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Loading next page...
 
/lp/pubmed/axitinib-versus-sorafenib-as-second-line-treatment-for-advanced-renal-fCbg0r02o5

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1470-2045
DOI
10.1016/S1470-2045(13)70093-7
pmid
23598172

Abstract

Journal

The Lancet OncologyPubmed

Published: Jun 28, 2013

There are no references for this article.